Incyte (INCY) Other Working Capital Changes (2010 - 2026)
Incyte (INCY) reported Other Working Capital Changes of -$9.2 million for Q1 2026, down 114.82% on a YoY basis from $62.0 million in Q1 2025, and up 85.87% quarter-over-quarter from -$65.0 million in Q4 2025.
Incyte (INCY) Other Working Capital Changes (2010 - 2026) Analysis & Trends
Incyte has reported Other Working Capital Changes for 17 years, with the latest figure at -$9.2 million in Q1 2026.
- For the quarter ending Q1 2026, Other Working Capital Changes fell 114.82% year-over-year to -$9.2 million; the trailing twelve-month figure through Mar 2026 stood at $85.0 million (up 70.06% YoY), and the FY2025 full-year result was $156.2 million, up 1607.35% from the prior year.
- Other Working Capital Changes for Q1 2026 stood at -$9.2 million, up from -$65.0 million in the prior quarter.
- The five-year high for Other Working Capital Changes was $86.4 million in Q2 2025, with the low at -$65.7 million in Q4 2024.
- Historically, Other Working Capital Changes has averaged $12.3 million across 5 years, with a median of $14.0 million in 2022.
- Annual changes were most pronounced in 2023 — Other Working Capital Changes sank 241.42% — and 2025, when it jumped 3554.0%.
- Incyte's Other Working Capital Changes stood at -$9.3 million in 2022, then tumbled by 111.17% to -$19.6 million in 2023, then tumbled by 235.61% to -$65.7 million in 2024, then gained by 1.08% to -$65.0 million in 2025, then surged by 85.87% to -$9.2 million in 2026.
- The last three Other Working Capital Changes figures came in at -$9.2 million (Q1 2026), -$65.0 million (Q4 2025), and $72.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.19 Mn |
| Mar 31, 2026 | -9.19 Mn |
| Dec 31, 2025 | -65.04 Mn |
| Dec 31, 2025 | -65.04 Mn |
| Sep 30, 2025 | 72.84 Mn |
| Sep 30, 2025 | 72.84 Mn |
| Jun 30, 2025 | 86.40 Mn |
| Jun 30, 2025 | 86.40 Mn |
| Mar 31, 2025 | 62.05 Mn |
| Mar 31, 2025 | 62.05 Mn |
| Dec 31, 2024 | -65.75 Mn |
| Dec 31, 2024 | -65.75 Mn |
| Sep 30, 2024 | 15.63 Mn |
| Sep 30, 2024 | 15.63 Mn |
| Jun 30, 2024 | 38.05 Mn |
| Jun 30, 2024 | 38.05 Mn |
| Mar 31, 2024 | 1.70 Mn |
| Mar 31, 2024 | 1.70 Mn |
| Dec 31, 2023 | -19.59 Mn |
| Dec 31, 2023 | -19.59 Mn |